Fierce Pharma August 9, 2024
Legend Biotech CEO Ying Huang, Ph.D., already had a lot on his plate when speculations of a potential geopolitical crackdown and the option of a buyout emerged.
The company’s CAR-T therapy Carvykti, partnered with Johnson & Johnson, is starting a key launch in second-line multiple myeloma, as the two partners are busy expanding capacity at multiple manufacturing sites simultaneously.
But lawmakers on the Congress’s Select Committee on the Chinese Communist Party recently requested an intelligence briefing on GenScript, which is Legend’s largest shareholder and former parent. And the inquiry included Legend, raising fears of a potential BIOSECURE Act-like crackdown.
Just as that risk clouds over Legend, a report in July suggested the company had received a takeover bid and had...
Today's Sponsors
Today's Sponsor